Matthew C Tattersall1, Mengye Guo1, Claudia E Korcarz1, Adam D Gepner1, Joel D Kaufman1, Kiang J Liu1, R Graham Barr1, Kathleen M Donohue1, Robyn L McClelland1, Joseph A Delaney1, James H Stein2. 1. From the Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison (M.C.T., C.E.K., A.D.G., J.H.S.); Department of Biostatistics (M.G.) and Department of Epidemiology (J.D.K., J.A.D.), University of Washington School of Public Health, Seattle; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (K.J.L.); Division of Pulmonary, Department of Medicine, Allergy and Critical Care Medicine Columbia University and Mailman School of Public Health, Columbia University, New York, NY (R.G.B.); and Division of Pulmonary, Department of Medicine, Allergy and Critical Care Medicine Columbia University, New York, NY (K.M.D.). 2. From the Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison (M.C.T., C.E.K., A.D.G., J.H.S.); Department of Biostatistics (M.G.) and Department of Epidemiology (J.D.K., J.A.D.), University of Washington School of Public Health, Seattle; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (K.J.L.); Division of Pulmonary, Department of Medicine, Allergy and Critical Care Medicine Columbia University and Mailman School of Public Health, Columbia University, New York, NY (R.G.B.); and Division of Pulmonary, Department of Medicine, Allergy and Critical Care Medicine Columbia University, New York, NY (K.M.D.). jhs@medicine.wisc.edu.
Abstract
OBJECTIVES: To identify and characterize an association between persistent asthma and cardiovascular disease (CVD) risk in the Multi-Ethnic Study of Atherosclerosis (MESA). APPROACH AND RESULTS: MESA is a longitudinal prospective study of an ethnically diverse cohort of individuals free of known CVD at its inception. The presence and severity of asthma were assessed in the MESA at examination 1. Persistent asthma was defined as asthmatics using controller medications (inhaled corticosteroids, leukotriene inhibitors, and oral corticosteroids) and intermittent asthma as asthmatics not using controller medications. Participants were followed up for a mean (SD) of 9.1 (2.8) years for development of incident CVD (coronary death, myocardial infarction, angina, stroke, and CVD death). Multivariable Cox regression models were used to assess associations of asthma and CVD. The 6792 participants were 62.2 (SD, 10.2) years old: 47% men (28% black, 22% Hispanic, and 12% Chinese). Persistent asthmatics (n=156), compared with intermittent (n=511) and nonasthmatics (n=6125), respectively, had higher C-reactive protein (1.2 [1.2] versus 0.9 [1.2] versus 0.6 [1.2] mg/L) and fibrinogen (379 [88] versus 356 [80] versus 345 [73] mg/dL) levels. Persistent asthmatics had the lowest unadjusted CVD-free survival rate of 84.1%, 95% confidence interval (78.9%-90.3%) compared with intermittent asthmatics 91.1% (88.5%-93.8%) and nonasthmatics 90.2% (89.4%-91%). Persistent asthmatics had greater risk of CVD events than nonasthmatics (hazard ratio [95% confidence interval], 1.6 [1.01-2.5]; P=0.040]), even after adjustment for age, sex, race, CVD risk factors, and antihypertensive and lipid medication use. CONCLUSIONS: In this large multiethnic cohort, persistent asthmatics had a higher CVD event rate than nonasthmatics.
OBJECTIVES: To identify and characterize an association between persistent asthma and cardiovascular disease (CVD) risk in the Multi-Ethnic Study of Atherosclerosis (MESA). APPROACH AND RESULTS:MESA is a longitudinal prospective study of an ethnically diverse cohort of individuals free of known CVD at its inception. The presence and severity of asthma were assessed in the MESA at examination 1. Persistent asthma was defined as asthmatics using controller medications (inhaled corticosteroids, leukotriene inhibitors, and oral corticosteroids) and intermittent asthma as asthmatics not using controller medications. Participants were followed up for a mean (SD) of 9.1 (2.8) years for development of incident CVD (coronary death, myocardial infarction, angina, stroke, and CVD death). Multivariable Cox regression models were used to assess associations of asthma and CVD. The 6792 participants were 62.2 (SD, 10.2) years old: 47% men (28% black, 22% Hispanic, and 12% Chinese). Persistent asthmatics (n=156), compared with intermittent (n=511) and nonasthmatics (n=6125), respectively, had higher C-reactive protein (1.2 [1.2] versus 0.9 [1.2] versus 0.6 [1.2] mg/L) and fibrinogen (379 [88] versus 356 [80] versus 345 [73] mg/dL) levels. Persistent asthmatics had the lowest unadjusted CVD-free survival rate of 84.1%, 95% confidence interval (78.9%-90.3%) compared with intermittent asthmatics 91.1% (88.5%-93.8%) and nonasthmatics 90.2% (89.4%-91%). Persistent asthmatics had greater risk of CVD events than nonasthmatics (hazard ratio [95% confidence interval], 1.6 [1.01-2.5]; P=0.040]), even after adjustment for age, sex, race, CVD risk factors, and antihypertensive and lipid medication use. CONCLUSIONS: In this large multiethnic cohort, persistent asthmatics had a higher CVD event rate than nonasthmatics.
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-12-18 Impact factor: 29.690
Authors: Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan Journal: Circulation Date: 2003-03-11 Impact factor: 29.690
Authors: Lara J Akinbami; Jeanne E Moorman; Cathy Bailey; Hatice S Zahran; Michele King; Carol A Johnson; Xiang Liu Journal: NCHS Data Brief Date: 2012-05
Authors: Pekka Jousilahti; Veikko Salomaa; Katri Hakala; Vesa Rasi; Elina Vahtera; Timo Palosuo Journal: Ann Allergy Asthma Immunol Date: 2002-10 Impact factor: 6.347
Authors: E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli Journal: High Blood Press Cardiovasc Prev Date: 2017-06-09
Authors: Cong-Lin Liu; Holger Wemmelund; Yi Wang; Mengyang Liao; Jes S Lindholt; Søren P Johnsen; Henrik Vestergaard; Cleverson Fernandes; Galina K Sukhova; Xiang Cheng; Jin-Ying Zhang; Chongzhe Yang; Xiaozhu Huang; Alan Daugherty; Bruce D Levy; Peter Libby; Guo-Ping Shi Journal: Arterioscler Thromb Vasc Biol Date: 2016-02-11 Impact factor: 8.311
Authors: Aivaras Cepelis; Ben M Brumpton; Lars E Laugsand; Håvard Dalen; Arnulf Langhammer; Imre Janszky; Linn B Strand Journal: Eur J Epidemiol Date: 2019-09-11 Impact factor: 8.082
Authors: Aivaras Cepelis; Ben M Brumpton; Vegard Malmo; Lars E Laugsand; Jan Pål Loennechen; Hanne Ellekjær; Arnulf Langhammer; Imre Janszky; Linn B Strand Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676
Authors: P Campos-Bedolla; R De-La-Cruz-Negrete; M H Vargas; E Torrejón-González; D Mejía-Mendoza; A Islas-Hernández; P Segura-Medina; G Córdoba-Rodríguez; S Orozco-Suárez; J L Arreola-Ramírez Journal: Physiol Res Date: 2019-12-19 Impact factor: 1.881
Authors: Matias E Pollevick; Kevin Y Xu; Grace Mhango; Emily G Federmann; Rajesh Vedanthan; Paula Busse; Fernando Holguin; Alex D Federman; Juan P Wisnivesky Journal: Chest Date: 2020-12-11 Impact factor: 9.410